U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Review Report: AbobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada, Inc.): Indication: To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Aug.

Cover of Pharmacoeconomic Review Report: AbobotulinumtoxinA (Dysport Therapeutic)

Pharmacoeconomic Review Report: AbobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada, Inc.): Indication: To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults [Internet].

Show details

Table 1Cost Comparison Table for Botulinum Toxin A for Cervical Dystonia

Drug/ComparatorStrengthDosage FormPrice ($)Recommended DoseAverage Cost per Treatment ($)aAverage Annualb Drug Cost ($)a
AbobotulinumtoxinA (Dysport Therapeutic)300 U
500 U		Vial for injection428.4000c 714.0000cInitially 500 U IM divided among affected muscles.Re-treatment doses ranged from 250 to 1,000 U in clinical trials. Re-treatment should not occur in intervals of less than 12 weeks.Initial: 714
Re-treatment: 428 to 1,428		2,428 to 6,426
IncobotulinumtoxinA (Xeomin)50 U
100 U		Vial for injection165.0000 330.0000The usual total dose does not exceed 200 U IM divided among affected muscles, but up to 300 U may be given. The period between re-treatments is recommended to be at least 12 weeks.Typically up to 660, may be up to 990Typically up to 3,300; may be up to 4,950
OnabotulinumtoxinA (Botox)50 U
100 U
200 U		Vial for injection178.5000 357.0000 714.0000Trial doses ranged from 140 U to 280 U IM divided among affected muscles; in clinical practice, doses from 200 U to 360 U have been used effectively. Repeat doses should be administered when clinical effect diminishes, but not more than every 2 months.
Maximum cumulative dose should not exceed 360 U in a 3-month period.		714 to 1,428d3,570 to 7,140d

IM = intramuscularly.

Note: All prices are from the Ontario Drug Benefit Formulary (accessed March 2017)7 unless otherwise indicated, and do not include dispensing fees.

a

Cost per treatment includes wastage of excess medication in vials.

b

Annual drug cost assumes initial dose and subsequent treatments at weeks 12, 24, 36, and 48.

c

Manufacturer’s submitted price.

d

Range of 200 U to 360 U every 12 weeks.

From: Summary

Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

  • Cite this Page
  • PDF version of this title (679K)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...